These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30188436)

  • 41. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention and treatment of postoperative nausea and vomiting.
    Kovac AL
    Drugs; 2000 Feb; 59(2):213-43. PubMed ID: 10730546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
    Navari RM
    Expert Opin Pharmacother; 2009 Mar; 10(4):629-44. PubMed ID: 19284365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
    Goodman M
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimum management of nausea and vomiting in cancer chemotherapy.
    Triozzi PL; Laszlo J
    Drugs; 1987 Jul; 34(1):136-49. PubMed ID: 3308410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
    Grunberg SM
    J Support Oncol; 2004; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
    Plosker GL; Milne RJ
    Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
    Slimano F; Netzer F; Borget I; Lemare F; Besse B
    Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New treatment options for chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    Support Care Cancer; 2004 Aug; 12(8):550-4. PubMed ID: 15232725
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
    Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Recommendations for the use of antiemetic drugs by the general practitioner].
    Fertani S; Pugliesi-Rinaldi A
    Rev Med Suisse; 2017 Jun; 13(566):1207-1211. PubMed ID: 28640567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Nathan PC
    Paediatr Drugs; 2003; 5(9):597-613. PubMed ID: 12956617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ondansetron: a review of its use as an antiemetic in children.
    Culy CR; Bhana N; Plosker GL
    Paediatr Drugs; 2001; 3(6):441-79. PubMed ID: 11437189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.
    de Boer-Dennert M; de Wit R; Schmitz PI; Djontono J; v Beurden V; Stoter G; Verweij J
    Br J Cancer; 1997; 76(8):1055-61. PubMed ID: 9376266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prophylaxis of chemotherapy-induced vomiting and nausea].
    Tóth J; Szántó J
    Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.